Heron Therapeutics Inc (FRA:AXD2) Stock Price, Trades & News

Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Financial Strength

1/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	0.32
Equity-to-Asset	0.04
Debt-to-Equity	15.5
Debt-to-EBITDA	-8.73
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-10	Distress Grey Safe
Beneish M-Score	-2.43	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-2.1
	3-Year EBITDA Growth Rate	68.7
	3-Year EPS without NRI Growth Rate	68.5
	3-Year FCF Growth Rate	50.4
	3-Year Book Growth Rate	-14.6
	Future 3-5Y Total Revenue Growth Rate Estimate	8.97

Momentum Rank

5/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	40.06
	9-Day RSI	32.73
	14-Day RSI	30.19
	3-1 Month Momentum %	8.56
	6-1 Month Momentum %	-34.68
	12-1 Month Momentum %	-59.41

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.53
	Quick Ratio	1.51
	Cash Ratio	0.49
	Days Inventory	646.02
	Days Sales Outstanding	200.04
	Days Payable	91.15

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-16.5
	Shareholder Yield %	35.15

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	71.12
	Operating Margin %	-6.94
	Net Margin %	-20.53
	EBITDA Margin %	-10.76
	FCF Margin %	-13.89
	OCF Margin %	-13.49
	ROA %	-12.69
	ROIC %	-8.25
	3-Year ROIIC %	715.91
	ROC (Joel Greenblatt) %	-18.21
	ROCE %	-15.54
	Moat Score	4
	Tariff Resilience Score	6

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	Forward PE Ratio	66.54
	PS Ratio	0.49
	PB Ratio	9.85
	Price-to-Tangible-Book	11.77
	EV-to-EBIT	-9.62
	EV-to-Forward-EBIT	43.95
	EV-to-EBITDA	-10.98
	EV-to-Revenue	1.18
	EV-to-Forward-Revenue	1.03
	EV-to-FCF	-8.54
	Price-to-GF-Value	0.28
	Earnings Yield (Greenblatt) %	-10.4
	FCF Yield %	-26.02

GF Value™: €1.28

FRA:AXD2

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with AXD2. Try a 7-Day Free Trial to check it out.

Heron Therapeutics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Heron Therapeutics Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-04 08:30	In 130 days
Third quarter earnings results for 2026	2026-11-04	In 129 days
Second quarter earnings conference call for 2026	2026-08-07 08:30	In 41 days
Second quarter earnings results for 2026	2026-08-07	In 40 days
General meeting for 2026	2026-06-11 09:00	0.35 (+0.00%)
First quarter earnings conference call for 2026	2026-05-11 08:30	1.04 (+0.00%)
First quarter earnings results for 2026	2026-05-11	1.04 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-02-26 08:30	0.91 (+0.00%)
Annual report for 2025	2026-02-26	0.91 (+0.00%)
Fourth quarter earnings results for 2025	2026-02-26	0.91 (+0.00%)

Show

Entries

Press Release

	Subject	Date
	Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value	2025-08-15
	Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress	2025-08-08
	Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile	2025-08-08
	Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025	2025-08-08
	Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025	2025-07-28
	Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates	2025-05-06
	Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations	2025-05-06
	Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer	2025-04-28
	Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025	2025-04-22
	Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates	2025-02-27

10/Page

Articles on Heron Therapeutics Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.